Table of Contents Author Guidelines Submit a Manuscript
Scientifica
Volume 2016, Article ID 6302376, 12 pages
http://dx.doi.org/10.1155/2016/6302376
Research Article

Regulation of Dopamine Uptake by Vasoactive Peptides in the Kidney

1Instituto de Investigaciones Cardiológicas ININCA, UBA-CONICET, Facultad de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina
2Cátedras de Anatomía e Histología, Facultad de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina
3Cátedras de Química Biológica, Facultad de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina
4Laboratorio de Medicina Experimental, Hospital Alemán, Buenos Aires, Argentina

Received 31 December 2015; Revised 19 June 2016; Accepted 3 July 2016

Academic Editor: Charles G. Plopper

Copyright © 2016 N. L. Rukavina Mikusic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M.-Z. Zhang and R. C. Harris, “Antihypertensive mechanisms of intra-renal dopamine,” Current Opinion in Nephrology and Hypertension, vol. 24, no. 2, pp. 117–122, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Tsuchida, G. Imai, Y. Shima, T. Satoh, and S. Owada, “Mechanism of sodium load-induced hypertension in non-insulin dependent diabetes mellitus model rats: defective dopaminergic system to inhibit Na-K-ATPase activity in renal epithelial cells,” Hypertension Research, vol. 24, no. 2, pp. 127–135, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Zeng, I. Armando, Y. Luo, G. M. Eisner, R. A. Felder, and P. A. Jose, “Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 294, no. 2, pp. H551–H569, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Bełtowski and G. Wójcicka, “Regulation of renal tubular sodium transport by cardiac natriuretic peptides: two decades of research,” Medical Science Monitor, vol. 8, no. 2, pp. RA39–RA52, 2002. View at Google Scholar · View at Scopus
  5. T. Sudoh, N. Minamino, K. Kangawa, and H. Matsuo, “C-Type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain,” Biochemical and Biophysical Research Communications, vol. 168, no. 2, pp. 863–870, 1990. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Barletta, C. Lazzeri, S. Vecchiarino et al., “Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans,” Hypertension, vol. 31, no. 3, pp. 802–808, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. N. G. Lumsden, R. S. Khambata, and A. J. Hobbs, “C-type Natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target,” Current Pharmaceutical Design, vol. 16, no. 37, pp. 4080–4088, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. P. R. Kalra, S. D. Anker, A. D. Struthers, and A. J. S. Coats, “The role of C-type natriuretic peptide in cardiovascular medicine,” European Heart Journal, vol. 22, no. 12, pp. 997–1007, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Ritter, A. D. Dean, S. L. Gluck, and J. E. Greenwald, “Natriuretic peptide receptors A and B have different cellular distributions in rat kidney,” Kidney International, vol. 48, no. 6, pp. 5758–5766, 1995. View at Google Scholar · View at Scopus
  10. T. Igaki, H. Itoh, S. Suga et al., “C-type natriuretic peptide in chronic renal failure and its action in humans,” Kidney International, vol. 49, pp. 144–147, 1996. View at Google Scholar
  11. I. Pham, S. Sediame, G. Maistre et al., “Renal and vascular effects of C-type and atrial natriuretic peptides in humans,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 273, no. 4, pp. R1457–R1464, 1997. View at Google Scholar · View at Scopus
  12. M. M. Gironacci, “Angiotensin-(1–7): beyond its central effects on blood pressure,” Therapeutic Advances in Cardiovascular Disease, vol. 9, no. 4, pp. 209–216, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Dilauro and K. D. Burns, “Angiotensin-(1–7) and its effects in the kidney,” TheScientificWorldJOURNAL, vol. 9, pp. 522–535, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. R. A. S. Santos and A. J. Ferreira, “Angiotensin-(1–7) and the renin-angiotensin system,” Current Opinion in Nephrology and Hypertension, vol. 16, no. 2, pp. 122–128, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. R. K. Handa, C. M. Ferrario, and J. W. Strandhoy, “Renal actions of angiotensin-(1–7): in vivo and in vitro studies,” American Journal of Physiology, vol. 270, no. 1, pp. F141–F147, 1996. View at Google Scholar · View at Scopus
  16. V. Vallon, K. Richter, N. Heyne, and H. Osswald, “Effect of intratubular application of angiotensin 1–7 on nephron function,” Kidney and Blood Pressure Research, vol. 20, no. 4, pp. 233–239, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. A. C. Aperia, “Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism,” Annual Review of Physiology, vol. 62, pp. 621–647, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. M. R. Citarella, M. R. Choi, M. M. Gironacci, C. Medici, A. H. Correa, and B. E. Fernández, “Urodilatin and dopamine: a new interaction in the kidney,” Regulatory Peptides, vol. 153, no. 1–3, pp. 19–24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. B. E. Fernández, A. H. Correa, and M. R. Choi, “Atrial natriuretic factor stimulates renal dopamine uptake mediated by natriuretic peptide-type A receptor,” Regulatory Peptides, vol. 124, no. 1–3, pp. 137–144, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. H. Correa, M. R. Choi, M. Gironacci, M. S. Valera, and B. E. Fernández, “Signaling pathways involved in atrial natriuretic factor and dopamine regulation of renal Na+, K+-ATPase activity,” Regulatory Peptides, vol. 138, no. 1, pp. 26–31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. R. Choi, M. R. Citarella, B. M. Lee, F. Lucano, and B. E. Fernández, “Urodilatin increases renal dopamine uptake: intracellular network involved,” Journal of Physiology and Biochemistry, vol. 67, no. 2, pp. 243–247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. R. Choi, A. H. Correa, V. del Valle Turco, F. A. Garcia, and B. E. Fernández, “Angiotensin II regulates extraneuronal dopamine uptake in the kidney,” Nephron Physiology, vol. 104, no. 4, pp. p136–p143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. R. Choi, C. Medici, M. M. Gironacci, A. H. Correa, and B. E. Fernández, “Angiotensin II regulation of renal dopamine uptake and Na+,K+-ATPase activity,” Nephron Physiology, vol. 111, no. 4, pp. 53–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. O. H. Lowry and J. A. López, “The determination of inorganic phosphate in the presence of labile phosphate esters,” The Journal of Biological Chemistry, vol. 162, pp. 421–428, 1946. View at Google Scholar · View at Scopus
  25. R. W. Albers, G. Rodríguez de Lores Arnaiz, and E. De Robertis, “Sodium-potassiumactivated ATPase and potassium-activated p-nitrophenylphosphatase: a comparison of their subcellular localizations in rat brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 53, pp. 557–564, 1965. View at Publisher · View at Google Scholar
  26. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at Google Scholar · View at Scopus
  27. S. Cuevas, V. A. Villar, P. A. Jose, and I. Armando, “Renal dopamine receptors, oxidative stress, and hypertension,” International Journal of Molecular Sciences, vol. 14, no. 9, pp. 17553–17572, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Burger, R. Bellomo, M. Chapman, S. Finfer, K. Hickling, and J. Myburgh, “Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group,” The Lancet, vol. 356, no. 9248, pp. 2139–2143, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Chamorro, M. A. Romera, J. L. Martinez-Melgar, C. Pardo, and J. A. Silva, “Dopamine dose and renal damage,” The Lancet, vol. 357, no. 9269, pp. 1707–1708, 2001. View at Publisher · View at Google Scholar
  30. H. H. Chen, K. J. Anstrom, M. M. Givertz et al., “Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial,” The Journal of the American Medical Association, vol. 310, no. 23, pp. 2533–2543, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Z. Marinosci, E. De Robertis, G. De Benedictis, and O. Piazza, “Dopamine use in intensive care: are we ready to turn it down?” Translational Medicine @ UniSa, vol. 4, pp. 90–94, 2012. View at Google Scholar
  32. J. A. Kellum and J. M. Decker, “Use of dopamine in acute renal failure: a meta-analysis,” Critical Care Medicine, vol. 29, no. 8, pp. 1526–1531, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. P. E. Marik, “Low-dose dopamine: a systematic review,” Intensive Care Medicine, vol. 28, no. 7, pp. 877–883, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. N. M. Kouyoumdzian, N. L. Rukavina Mikusic, M. C. Kravetz et al., “Atrial natriuretic peptide stimulates dopamine tubular transport by organic cation transporters: a novel mechanism to enhance renal sodium excretion,” PLoS ONE, vol. 11, no. 7, Article ID e0157487, 2016. View at Publisher · View at Google Scholar
  35. G. Ciarimboli and E. Schlatter, “Regulation of organic cation transport,” Pflugers Archiv European Journal of Physiology, vol. 449, no. 5, pp. 423–441, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Eisenhofer, “The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines,” Pharmacology & Therapeutics, vol. 91, no. 1, pp. 35–62, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Koepsell, K. Lips, and C. Volk, “Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications,” Pharmaceutical Research, vol. 24, no. 7, pp. 1227–1251, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Pietig, T. Mehrens, J. R. Hirsch, I. Çetinkaya, H. Piechota, and E. Schlatter, “Properties and regulation of organic cation transport in freshly isolated human proximal tubules,” Journal of Biological Chemistry, vol. 276, no. 36, pp. 33741–33746, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. K. J. Koller, D. G. Lowe, G. L. Bennett et al., “Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP),” Science, vol. 252, no. 5002, pp. 120–123, 1991. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Canaan-Kuhl, R. L. Jamison, B. D. Myers, and R. E. Pratt, “Identification of ‘B’ receptor for natriuretic peptide in human kidney,” Endocrinology, vol. 130, pp. 550–552, 1992. View at Google Scholar
  41. D. Ritter, A. D. Dean, S. L. Gluck, and J. E. Greenwald, “Natriuretic peptide receptors A and B have different cellular distributions in rat kidney,” Kidney International, vol. 48, no. 6, pp. 1758–1766, 1995. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Brown and Z. Zuo, “Renal receptors for atrial and C-type natriuretic peptides in the rat,” American Journal of Physiology-Renal Fluid and Electrolyte Physiology, vol. 263, no. 1, pp. F89–F96, 1992. View at Google Scholar · View at Scopus
  43. S. Suga, K. Nakao, H. Itoh et al., “Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of ‘vascular natriuretic peptide system’,” Journal of Clinical Investigation, vol. 90, pp. 1145–1149, 1992. View at Publisher · View at Google Scholar
  44. M. M. Gironacci, N. A. Longo Carbajosa, J. Goldstein, and B. D. Cerrato, “Neuromodulatory role of angiotensin-(1-7) in the central nervous system,” Clinical Science, vol. 125, no. 2, pp. 57–65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Tsuda, “Renin-angiotensin system and sympathetic neurotransmitter release in the central nervous system of hypertension,” International Journal of Hypertension, vol. 2012, Article ID 474870, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. R. A. S. Santos, A. C. Simoes e Silva, C. Maric et al., “Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8258–8263, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. R. A. S. Santos, M. J. Campagnole-Santos, N. C. V. Baracho et al., “Characterization of a new angiotensin antagonist selective for angiotensin-(1–7): evidence that the actions of angiotensin-(1–7) are mediated by specific angiotensin receptors,” Brain Research Bulletin, vol. 35, no. 4, pp. 293–298, 1994. View at Publisher · View at Google Scholar · View at Scopus
  48. J. B. Su, “Different cross-talk sites between the renin-angiotensin and the kallikrein-kinin systems,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 15, no. 4, pp. 319–328, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Caruso-Neves, L. S. Lara, L. B. A. Rangel, A. L. Grossi, and A. G. Lopes, “Angiotensin-(1–7) modulates the ouabain-insensitive Na+-ATPase activity from basolateral membrane of the proximal tubule,” Biochimica et Biophysica Acta, vol. 1467, no. 1, pp. 189–197, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. I. H. Mills and L. F. O. Obika, “The effect of adrenergic and dopamine receptor blockade on the kallikrein and renal response to intra arterial infusion of dopamine in dogs,” Journal of Physiology, vol. 263, no. 1, pp. 150–151, 1976. View at Google Scholar · View at Scopus
  51. H. Maeda, M. Sasaguri, T. Sakai et al., “Roles of renal dopamine and kallikrein-kinin systems in antihypertensive mechanisms of exercise in rats,” Hypertension Research, vol. 23, no. 5, pp. 511–519, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. O. Iimura, K. Shimamoto, N. Ura et al., “The pathophysiological role of renal dopamine, kallikrein kinin and prostaglandin systems in essential hypertension,” Agents and Actions Supplements, vol. 22, pp. 247–256, 1987. View at Google Scholar · View at Scopus
  53. T. Huo and D. P. Healy, “Prostaglandin E2 production in rat IMCD cells I. Stimulation by dopamine,” American Journal of Physiology-Renal Fluid and Electrolyte Physiology, vol. 261, no. 4, pp. F647–F654, 1991. View at Google Scholar · View at Scopus
  54. T. Huo, A. Grenader, P. Blandina, and D. P. Healy, “Prostaglandin E2 production in rat IMCD cells II. Possible role for locally formed dopamine,” American Journal of Physiology—Renal Fluid and Electrolyte Physiology, vol. 261, no. 4, pp. F655–F662, 1991. View at Google Scholar · View at Scopus
  55. M. A. Clark, E. A. Tallant, E. Tommasi, S. Bosch, and D. I. Diz, “Angiotensin-(1–7) reduces renal angiotensin II receptors through a cyclooxygenase-dependent mechanism,” Journal of Cardiovascular Pharmacology, vol. 41, no. 2, pp. 276–283, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. L. M. Shulman and D. A. Fox, “Dopamine inhibits mammalian photoreceptor Na+,K+-ATPase activity via a selective effect on the α3 isozyme,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 15, pp. 8034–8039, 1996. View at Publisher · View at Google Scholar · View at Scopus
  57. W. O. Sampaio, R. A. S. Dos Santos, R. Faria-Silva, L. T. Da Mata Machado, E. L. Schiffrin, and R. M. Touyz, “Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways,” Hypertension, vol. 49, no. 1, pp. 185–192, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. W. O. Sampaio, A. A. S. Nascimento, and R. A. Souza dos Santos, “Systemic and regional hemodynamic effects of angiotensin-(1–7) in rats,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 284, no. 6, pp. H1985–H1994, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Dharmani, M. R. Mustafa, F. I. Achike, and M.-K. Sim, “Effects of angiotensin 1–7 on the actions of angiotensin II in the renal and mesenteric vasculature of hypertensive and streptozotocin-induced diabetic rats,” European Journal of Pharmacology, vol. 561, no. 1–3, pp. 144–150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Brouwers, I. Smolders, A. Massie, and A. G. Dupont, “Angiotensin II Type 2 receptor-mediated and nitric oxide-dependent renal vasodilator response to compound 21 unmasked by angiotensin-converting enzyme inhibition in spontaneously hypertensive rats in vivo,” Hypertension, vol. 62, no. 5, pp. 920–926, 2013. View at Publisher · View at Google Scholar
  61. M. A. Costa, R. Elesgaray, A. Loria, A. M. Balaszczuk, and C. Arranz, “Vascular and renal effects of dopamine during extracellular volume expansion: role of nitric oxide pathway,” Life Sciences, vol. 78, no. 14, pp. 1543–1549, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. U. Venkatakrishnan, C. Chen, and M. F. Lokhandwala, “The role of intrarenal nitric oxide in the natriuretic response to dopamine-receptor activation,” Clinical and Experimental Hypertension, vol. 22, no. 3, pp. 309–324, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Del Ry, C. Passino, M. Emdin, and D. Giannessi, “C-type natriuretic peptide and heart failure,” Pharmacological Research, vol. 54, no. 5, pp. 326–333, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Rubattu, S. Sciarretta, A. Morriello, C. Calvieri, A. Battistoni, and M. Volpe, “NPR-C: a component of the natriuretic peptide family with implications in human diseases,” Journal of Molecular Medicine, vol. 88, no. 9, pp. 889–897, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. S. V. B. Pinheiro and A. C. Simões e Silva, “Angiotensin converting enzyme 2, angiotensin-(1–7), and receptor mas axis in the kidney,” International Journal of Hypertension, vol. 2012, Article ID 414128, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. R. K. Handa, C. M. Ferrario, and J. W. Strandhoy, “Renal actions of angiotensin-(1-7): in vivo and in vitro studies,” American Journal of Physiology, vol. 270, no. 1, pp. F141–F147, 1996. View at Google Scholar · View at Scopus
  67. N. H. Garcia and J. L. Garvin, “Angiotensin 1–7 has a biphasic effect on fluid absorption in the proximal straight tubule,” Journal of the American Society of Nephrology, vol. 5, no. 4, pp. 1133–1138, 1994. View at Google Scholar · View at Scopus
  68. M. G. López Ordieres, M. M. Gironacci, G. Rodríguez de Lores Arnaiz, and C. Peña, “Effect of angiotensin-(1–7) on ATPase activities in several tissues,” Regulatory Peptides, vol. 77, no. 1–3, pp. 135–139, 1998. View at Publisher · View at Google Scholar · View at Scopus
  69. S. V. B. Pinheiro and A. C. Simões e Silva, “Angiotensin converting enzyme 2, angiotensin-(1-7), and receptor MAS axis in the kidney,” International Journal of Hypertension, vol. 2012, Article ID 414128, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. R. A. S. Dos Santos, K. T. Passaglio, J. B. Pesquero, M. Bader, and A. C. S. E Silva, “Interactions between angiotensin-(1–7), kinins, and angiotensin II in kidney and blood vessels,” Hypertension, vol. 38, no. 3, part 2, pp. 660–664, 2001. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. Ren, J. L. Garvin, and O. A. Carretero, “Vasodilator action of angiotensin-(1–7) on isolated rabbit afferent arterioles,” Hypertension, vol. 39, no. 3, pp. 799–802, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Patzak, F. Kleinmann, E. Y. Lai, E. Kupsch, A. Skelweit, and R. Mrowka, “Nitric oxide counteracts angiotensin II induced contraction in efferent arterioles in mice,” Acta Physiologica Scandinavica, vol. 181, no. 4, pp. 439–444, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Stegbauer, S. A. Potthoff, I. Quack et al., “Chronic treatment with angiotensin-(1–7) improves renal endothelial dysfunction in apolipoproteinE-deficient mice,” British Journal of Pharmacology, vol. 163, no. 5, pp. 974–983, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. C. M. Ferrario, J. Jessup, P. E. Gallagher et al., “Effects of renin-angiotensin system blockade on renal angiotensin-(1–7) forming enzymes and receptors,” Kidney International, vol. 68, no. 5, pp. 2189–2196, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. K. Da Silveira, L. C. Barroso, A. T. Vieira et al., “Beneficial effects of the activation of the angiotensin-(1–7) mas receptor in a murine model of adriamycin-induced nephropathy,” PLoS ONE, vol. 8, no. 6, Article ID e66082, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. L. G. Maia, M. C. Ramos, L. Fernandes, M. H. C. de Carvalho, M. J. Campagnole-Santos, and R. A. S. dos Santos, “Angiotensin-(1–7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats,” Journal of Cardiovascular Pharmacology, vol. 43, no. 5, pp. 685–691, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Igase, H. Yokoyama, and C. M. Ferrario, “Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7),” Therapeutic Advances in Cardiovascular Disease, vol. 5, no. 6, pp. 297–304, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. W.-N. Zong, X.-H. Yang, X.-M. Chen et al., “Regulation of angiotensin-(1–7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure,” Acta Pharmacologica Sinica, vol. 32, no. 11, pp. 1345–1350, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. V. Sukumaran, P. T. Veeraveedu, N. Gurusamy et al., “Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis,” Life Sciences, vol. 90, no. 7-8, pp. 289–300, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. M. J. A. Kocks, A. T. Lely, F. Boomsma, P. E. de Jong, and G. Navis, “Sodium status and angiotensin-converting enzyme inhibition: effects on plasma angiotensin-(1–7) in healthy man,” Journal of Hypertension, vol. 23, no. 3, pp. 597–602, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. A. C. Simões E Silva, K. D. Silveira, A. J. Ferreira, and M. M. Teixeira, “ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis,” British Journal of Pharmacology, vol. 169, no. 3, pp. 477–492, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. A. C. Simões e Silva and M. M. Teixeira, “ACE inhibition, ACE2 and angiotensin-(1–7) axis in kidney and cardiac inflammation and fibrosis,” Pharmacological Research, vol. 107, pp. 154–162, 2016. View at Publisher · View at Google Scholar